The London Corporate team at international law firm DAC Beachcroft has underlined its equity capital markets credentials with the announcement of three admissions to UK public markets in March on which it advised.

First, DAC Beachcroft advised nominated adviser, Cairn Financial Advisers LLP, and broker, Turner Pope Investments (TPI) Ltd, on the imminent admission of life sciences company, SkinBioTherapeutics, to the AIM market of the London Stock Exchange.

UK-based SkinBioTherapeutics will use its admission to AIM to fund the growth of its technology platform, SkinBiotix, which it has developed to research skin-related applications for cosmetics and healthcare. DAC Beachcroft's team on the deal was led by Clive Garston with support from Legal Director, Michelle Jones.

Meanwhile, a second DAC Beachcroft team led by Corporate Partner, Jonathan Deverill, and assisted by Michelle Jones and solicitor Lucinda Hicks advised First Sentinel plc on its recent IPO. 

First Sentinel is an alternative investment company, registered with the FCA as a small authorised UK AIFM, which intends to provide growth capital for public and private company investments.

Lastly, Jonathan Deverill, again with the assistance of Michelle Jones and Lucinda Hicks, also advised finnCap and Throgmorton Street Capital on Anglo African Oil & Gas (AAOG) plc's successful admission to AIM. AAOG is an independent oil and gas developer with oil-producing assets in the Republic of Congo.

DAC Beachcroft's London Corporate team is part of a national practice of more than 40 lawyers, which acted on more than 90 completed transactions in 2016 with an aggregate value of more than £1 billion.  Earlier this month, the firm appointed Nick Fothergill as a Partner in its London Corporate team from Watson Farley & Williams.

Nick Gibbon, Partner and head of DAC Beachcroft's London Corporate team, said: "Our Equity Capital Markets practice is thriving.  We were delighted to be involved in these three significant admissions in the space of a single month."

"In spite of challenging market conditions, we are also working on a number of similar transactions for other clients.  Indeed, March has been a very busy month across the board for our Equity Capital Markets team, which was also involved in secondary fundraisings for companies including Valirx, Orogen Gold plc and Sabien Technology Group plc."